Glow Lifetech Corp
Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products. The company engages in the commercialization of plant-based MyCell technology delivery system; water-soluble ingredients; customized blends; powder-based Capsules, and market-ready products, as well as precision-dosed capsules. It has exclusive North American rights for the production,… Read more
Glow Lifetech Corp (GLWLF) - Net Assets
Latest net assets as of September 2025: $2.22 Million USD
Based on the latest financial reports, Glow Lifetech Corp (GLWLF) has net assets worth $2.22 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.70 Million) and total liabilities ($1.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.22 Million |
| % of Total Assets | 59.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 61.21 |
Glow Lifetech Corp - Net Assets Trend (2019–2024)
This chart illustrates how Glow Lifetech Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Glow Lifetech Corp (2019–2024)
The table below shows the annual net assets of Glow Lifetech Corp from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.57 Million | +349.29% |
| 2023-12-31 | $-1.03 Million | -188.52% |
| 2022-12-31 | $1.16 Million | -66.10% |
| 2021-12-31 | $3.44 Million | +1197.72% |
| 2020-12-31 | $-312.97K | -96.23% |
| 2019-12-31 | $-159.49K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Glow Lifetech Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1763219100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $21.01 Million | 817.34% |
| Total Equity | $2.57 Million | 100.00% |
Glow Lifetech Corp Competitors by Market Cap
The table below lists competitors of Glow Lifetech Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shivam Autotech Limited
NSE:SHIVAMAUTO
|
$5.39 Million |
|
PT DFI Retail Nusantara Tbk
JK:HERO
|
$5.39 Million |
|
Nuintek Co.Ltd
KQ:012340
|
$5.39 Million |
|
Lupatech S.A
SA:LUPA3
|
$5.40 Million |
|
Grounds Real Estate Development AG
XETRA:AMMN
|
$5.39 Million |
|
Oxbridge Re Holdings Ltd
NASDAQ:OXBR
|
$5.39 Million |
|
Nocopi Technologies Inc
OTCQB:NNUP
|
$5.39 Million |
|
ECARX Holdings Inc. Warrants
NASDAQ:ECXWW
|
$5.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Glow Lifetech Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,031,096 to 2,570,389, a change of 3,601,485.
- Net loss of 2,657,323 reduced equity.
- New share issuances of 2,509,648 increased equity.
- Other factors increased equity by 3,749,160.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.66 Million | -103.38% |
| Share Issuances | $2.51 Million | +97.64% |
| Other Changes | $3.75 Million | +145.86% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Glow Lifetech Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $0.04 | x |
| 2020-12-31 | $-0.01 | $0.04 | x |
| 2021-12-31 | $0.06 | $0.04 | x |
| 2022-12-31 | $0.02 | $0.04 | x |
| 2023-12-31 | $-0.02 | $0.04 | x |
| 2024-12-31 | $0.02 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Glow Lifetech Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -103.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -317.79%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.45x
- Recent ROE (-103.38%) is above the historical average (-104.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-40.19K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-122.18K |
| 2021 | -329.33% | 0.00% | 0.00x | 1.10x | $-11.66 Million |
| 2022 | -194.96% | 0.00% | 0.00x | 1.98x | $-2.39 Million |
| 2023 | 0.00% | -3617.40% | 0.03x | 0.00x | $-1.49 Million |
| 2024 | -103.38% | -317.79% | 0.22x | 1.45x | $-2.91 Million |
Industry Comparison
This section compares Glow Lifetech Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Glow Lifetech Corp (GLWLF) | $2.22 Million | 0.00% | 0.67x | $5.39 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |